Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths

This article was originally published in PharmAsia News

14 Aug 2007
News

PharmAsia News @PharmAsiaNews pharmasia@informa.com

Executive Summary

A decision to withdraw Novartis' Prexige (lumiracoxib) in Australia after two patients died from serious liver injury following treatment with the drug is likely to impact the outcome of FDA's decision on a pending NDA for the COX-2 inhibitor

Already Registered? Sign in to continue reading.

New to Scrip? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

SC066439

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

SC066439

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths

News

Executive Summary

Related Content

Prexige Review Will Not Include FDA Arthritis Drugs Advisory Committee

FDA Cold-Cox Merck; Arcoxia “Not Approvable” For Osteoarthritis

Novartis Bullish About Prexige; Anticipates Blockbuster Potential

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert